Like marijuana before it, psychedelics once considered illicit, are now going mainstream. Although the substances, their effects, and the chemical compounds at their core are quite different, psychedelics—specifically psilocybin—have followed the trail blazed by marijuana to mainstream acceptance and Wall Street excitement.
Psychedelic marketplace is forecasted to be nearly a $6.9 billion business by 2027.
A new market study of the U.S. psychedelic space forecasts that the market is projected to grow at 16.3%. Factors such as increasing prevalence of depression and mental disorders drive that growth. The Data Bridge Market Research report notes that the market is expected to total approximately $6.8 billion by 2027, up from $2 billion in 2019. In addition, the report specifically highlights the growing acceptance of psychedelics for treating depression along with the increasing prevalence of depression and mental disorders as significant factors in that anticipated growth.
This expected increase isn’t going unnoticed by investors. The first psychedelic company recently entered the public markets with an initial public offering price of $17 per share; the price shot up to close at $38.39 within only a few days.
“Psychedelics have been put on the back burner for 50 years and are now having a Renaissance, the hundreds of studies that have been conducted over the past 10 to 20 years” at highly respected institutions have made it clear that psychedelic molecules have “tremendous potential for patients with depression, PTSD , addiction anxiety, obsessive-compulsive disorder, major depressive disorder and alcohol dependence, among others, with some positive results to date.”
No longer a fringe topic, psychedelics are quickly becoming a viable option, not only as a potential breakthrough therapeutic tool for mental and physical health, but also a massive market for investment opportunity.
For the first time, we are seeing a trajectory emerge for the psychedelic industry. Smart capital is moving in to take advantage of the opportunity to invest in the next frontier. Despite being an industry in its early stages, the potential for psychedelic health care is growing.
Here are just a few indicators of the wave of interest in psychedelics:
- In the past year alone, dozens of companies have moved into the space, either as psychedelic-only companies or from other industries such as bioscience, pharmaceuticals and cannabis.
- A number of cannabis scientists in Canada and the U.S. have shifted to psychedelics or are now in both industries.
- Investors are turning their attention, and more importantly their capital, to this advancing industry for three key reasons: the global need for effective mental health treatments, evolving legislation and regulation, and widely supportive public opinion
Why Magic Mushrooms ?
Just a few decades ago, the approach would have been unfathomable to many. Using psychedelics to treat people with PTSD? Depression? Addiction? To make them stop smoking? To perhaps treat Alzheimer’s? times have changed, and today, as with so many other cultural shifts, people are taking a second look at some of the things considered taboo not so long ago.
Benefits of Magic Mushrooms
- Increase of “openness” and other beneficial shifts in personality.
- Smoking cessation and other addictions.
- Dissolve your ego and increase creativity.
- Cure depression , Anxiety and PTSD .
